Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of JNJ-54861911 in early Alzheimer's disease
NL-OMON44804Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atabecestat in Alzheimer's disease (AD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Long-term safety and tolerability and MRI safety monitoring. Started Dec 2015; status: active, not recruiting.
02
Drugs
atabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON44804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44804.